A Study of Endoscopic Sleeve Gastroplasty for Obesity in Ulcerative Colitis

Last updated: November 13, 2024
Sponsor: Mayo Clinic
Overall Status: Active - Recruiting

Phase

N/A

Condition

Obesity

Ulcerative Colitis

Inflammatory Bowel Disease

Treatment

Lifestyle Intervention

Apollo Endoscopic Suture System

Clinical Study ID

NCT05739162
22-007643
  • Ages 22-69
  • All Genders

Study Summary

The purpose of this research is to gather information on the safety and effectiveness of Endoscopic Sleeve Gastroplasty (ESG) for weight loss in a population of obese UC patients undergoing colectomy with eventual IPAA.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • BMI 30-50 kg/m2 for at least 6 months prior to ESG

  • Diagnosis of UC with plans to undergo or who have already undergone colectomy aspart of a plan to pursue eventual 3-stage ileal pouch anal anastomosis (IPAA)

  • Willing to adhere to the diet and behavior modifications required for ESG

  • Able to follow the visit schedule

  • Able to provide informed consent

  • If female, be either post-menopausal, surgically sterile, or agree to practice birthcontrol during year of study and have negative serum Human Chorionic Gonadotropin (HCG) at screening/baseline

Exclusion

Exclusion Criteria:

  • Prior gastric or bariatric surgery or other alteration to upper gastrointestinalanatomy which would preclude safe or technical performance of ESG

  • Current or recent (last six months) gastric or duodenal ulceration

  • Esophageal or gastric varices

  • Significant motility disorder of the esophagus or stomach

  • Large hiatal hernia measuring >5 cm or ≤ 5 cm and associated with severegastroesophageal reflux

  • Severe coagulopathy, hepatic insufficiency, or cirrhosis

  • Gastric mass

  • Presence of any other medical condition which precludes safe performance of electiveendoscopy such as poor general health and/or history of severe hepatic, cardiac, orpulmonary disease

  • Serious or uncontrolled psychiatric illness which may compromise patientunderstanding of procedure or compliance with follow-up visits

  • Unwilling to participate in an established diet and behavior modification program,with routine follow-up

  • Ongoing corticosteroid use at a dose of >5 mg daily

  • Daily use of anti-inflammatory agents such as non-steroidal medications, oranticoagulants without medical supervision

  • Alcohol or drug addiction

  • Females who are pregnant, nursing, or planning pregnancy within the next year

  • Concomitant use of or unwillingness to avoid any use of weight loss medications,weight loss supplements, or weight loss herbal preparations

  • Has a condition or is in a situation which in the investigator's opinion may put thesubject at significant risk or may interfere significantly with the subject'sparticipation in the study

Study Design

Total Participants: 12
Treatment Group(s): 2
Primary Treatment: Lifestyle Intervention
Phase:
Study Start date:
September 20, 2023
Estimated Completion Date:
January 31, 2026

Connect with a study center

  • Mayo Clinic Minnesota

    Rochester, Minnesota 55905
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.